This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pershing Square Delivers Votes For Allergan Special Meeting to Push Valeant Deal

NEW YORK ( The Deal) -- Activist investor Pershing Square Capital Management's efforts to push Allergan (AGN - Get Report)  into accepting a hostile blockbuster bid by Valeant Pharmaceuticals International (VRX - Get Report)  moved to the next stage late Friday after the dissident investor presented the required consents of shareholders to hold a special shareholder meeting at the target.

Pershing submitted consents of shareholders representing 31% of Allergan's shareholders, slightly more than the 25% of outstanding shares the activist fund needed to submit to have the meeting take place based on Allergan's bylaws.

Bill Ackman, who runs Pershing Square, is seeking to hold the meeting for the purpose of giving shareholders the opportunity to vote for removing six of Allergan's nine incumbent directors, as part of his effort to drive Allergan, best known as the maker of Botox, to accept Canadian-based Valeant's hostile bid.

Ackman has been pressing to have Irvine, Calif.-based Allergan sell itself to Canada's Valeant, which is pushing an unsolicited cash-and-stock $54 billion tender offer to buy the Botox maker. That offer is now set to expire Dec. 31 after being pushed back from Aug. 15 earlier this month because of concerns that the dissident investor did not have a sufficiently large number of investors agreeing to back his campaign. The tender offer is also part of an effort to gauge shareholder sentiment for the potential deal and to drive Allergan's board to the negotiating table.

The next step is for Allergan to set a date for the meeting. Its bylaws require that the meeting take place no later than 120 days after the consents were delivered so it is likely the company, which is fighting the offer tooth and nail, will challenge the votes for the meeting at the same time that it seeks to delay it until Dec. 22.

Officials from both Pershing and Allergan did not return requests for comment on when the meeting might take place.

Pershing owns most of a 9.7% Allergan stake and as a result only needed the backing of 15.3% of the company's shareholders to call the meeting. But Allergan bylaw requirements that investors that indicate consent to calling a special meeting sign a document saying they plan to hold onto their shares until that meeting takes place has made it harder for the hedge fund to find qualifying shareholders.

In a statement, Pershing said that, over the next few weeks, it expects to deliver additional requests from shareholders who are in the process of completing the required documentation. Specifically, any participating investor that sells shares prior to the meeting can no longer have those shares counted towards the minimum 25% Pershing needs to call the meeting.

Nevertheless, a person familiar with the situation noted that the investors agreeing to participate are long-term investors that Pershing believes will be there at the time of the meeting. Pershing's Ackman has received the backing of 35 large investors and is seeking additional support from smaller investors in an effort to make sure that he still has more than 25% at the time of the meeting.

"It's a miracle Pershing got investors to participate," said an attorney familiar with the situation.

The attorney noted that in most cases investors seeking to consent to participate in a vote to hold a special shareholder meeting must fill out a one page form. At Allergan, he noted, each institution must fill out a multiple page questionnaire and provide numerous verification letters. Investors must provide a spreadsheet with information about every trade the fund has made in Allergan over the previous two years, a prospect the dissident has argued is complicated and time consuming and raises proprietary trading issues.

"Many funds consider their trading info proprietary and don't want to disclose it," the attorney said.

In one case, he added, a shareholder put together a package that was 174 pages long with 85 signatures in it. "It probably took tens of thousands of dollars of legal work and lots of internal time," he said.

In a statement Allergan said its board "continues to believe that Valeant's unsolicited exchange offer is grossly inadequate and substantially undervalues Allergan."

Pershing also launched a pre-emptive strike as part of its effort to make it more difficult for Allergan to contest the validity of some of the consents submitted. At the same time that it submitted the consents to the company, Pershing also filed a lawsuit in Delaware Court of Chancery seeking to have the court validate the consents that were filed.

The submission of the consents and the Delaware lawsuit comes after a California federal judge on Thursday declined to expedite an insider trading lawsuit filed against Pershing by Allergan.

The decline to expedite by the court was a major victory for Pershing, people familiar with the situation said. For one thing, the California court indicated that it had no intension of inserting itself into issues about calling special shareholder meetings, which it said was firmly within the jurisdiction of the Delaware court.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGN $216.52 -0.73%
VRX $33.96 4.00%
AAPL $94.24 0.64%
FB $118.00 -0.48%
GOOG $695.82 -0.34%


Chart of I:DJI
DOW 17,701.19 -189.97 -1.06%
S&P 500 2,058.43 -23.00 -1.10%
NASDAQ 4,759.1050 -58.4890 -1.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs